Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

BACKGROUND: The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 22/99 trial was to characterize the specific subset of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Sabine, Klingbiel, Dirk, Aebi, Stefan, Goldhirsch, Aron, Mamot, Christoph, Munzone, Elisabetta, Nolè, Franco, Oehlschlegel, Christian, Pagani, Olivia, Pestalozzi, Bernhard, Rochlitz, Christoph, Thürlimann, Beat, von Moos, Roger, Weder, Patrik, Zaman, Khalil, Ruhstaller, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734335/
https://www.ncbi.nlm.nih.gov/pubmed/31500588
http://dx.doi.org/10.1186/s12885-019-6105-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734335/
https://www.ncbi.nlm.nih.gov/pubmed/31500588
http://dx.doi.org/10.1186/s12885-019-6105-3

Ejemplares similares